Sun Pharmaceutical Industries LtdNSE: SUNPHARMA
Open the Sun Pharmaceutical Industries Ltd page
Follow Sun Pharmaceutical Industries LtdFree account. Get a note when Sun Pharmaceutical Industries Ltd files.
Q1 FY27 results analysis · July 31, 2026

Sun Pharmaceutical Industries Ltd (SUNPHARMA) Q1 FY27 Results Analysis: PAT Jumps 27%, EBITDA Margin Compresses 220 bps

+27.0%PAT year on year, Rs. 2,895.00 Cr
Cofacto ResearchPublished July 31, 20262 min readPositive read
Quick summary

Sun Pharmaceutical Industries Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 15,300.00 Cr (+10.50% YoY) and PAT growth of +27.00% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 31, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 15,300.00 Cr (+10.50% YoY)
PAT (Q1)Rs. 2,895.00 Cr (+27.00% YoY)
EBITDA margin28.90% (-220 bps YoY)
EPS (Q1)Rs. 12.10 (+27.40% YoY)
Market capRs. 477,671.17 Cr
CMPRs. 1,990.50

Quarter Snapshot

Q1 revenue growth of 10.5% YoY exceeded management's high single-digit guidance, driven by strong India performance (+16%) and Innovative Medicines (+12.8% USD). PAT grew 27% YoY, though EBITDA margin contracted 220bps due to cost pressures. US generics remained weak (-9.7% USD). The Organon acquisition is on track for early 2027 closing, providing a long-term catalyst. Overall, a solid quarter with a revenue beat but margin compression warrants caution.

Key Investment Insights

Key Positives

  • Revenue grew 10.5% YoY to Rs.152,999 Mn, exceeding management's high single-digit guidance
  • PAT grew 27.0% YoY to Rs.28,948 Mn, aided by lower exceptional items
  • India formulations grew 16.0% YoY, gaining market share to 8.5% (up 30 bps)
  • Innovative Medicines segment grew 12.8% YoY in USD, now 21.9% of sales
  • Normalized PAT (ex-exceptionals) grew 3.1% YoY to Rs.30,894 Mn
  • Organon acquisition on track with stockholder approval received and closing expected early 2027

Risk Factors

  • US formulations declined 9.7% YoY in USD due to pricing pressure and compliance issues
  • EBITDA margin contracted 220 bps YoY to 28.9%, driven by higher employee costs and acquisition expenses
  • Employee benefits expense grew 15.2% YoY, outpacing revenue growth
  • Finance costs increased 33.3% YoY, reflecting higher interest burden
  • Effective tax rate of 29.0% exceeded the expected 25.168% due to non-deductible exceptional items
  • R&D spend at 5.4% of sales was below the 6-7% guidance range

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.